Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Wim van der Vijgh

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Procedures

High Pressure Liquid Chromatography

Concepts & Ideas

Disorders

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
49
Bast, Aalt
35
PINEDO, HERBERT
32
Netelenbos, Coen
22
Haenen, Guido
21
Lips, Paul
20
Boven, Epie
19
Vermorken, Jan
14
Barto, Rob
13
Peters, Godefridus
13
van Acker, Saskia
11
Verschraagen, Miranda
10
Van Ginkel, FC
9
van Groeningen, Cees
9
Kedde, Marc
9
Abou El Hassan, Mohamed

Sign-in to see all Coauthors

Publications

TOP 3
Jacobs Hilde; van der Vijgh Wim J F; Koek Ger H; Draaisma Guy J J; Moalin Mohamed; van Strijdonck Gino P F; Bast Aalt; Haenen Guido R M M
Characterization of the glutathione conjugate of the semisynthetic flavonoid monoHER.
Bruynzeel A M E; Niessen H W M; Bronzwaer J G F; van der Hoeven J J M; Berkhof J; Bast A; van der Vijgh W J F; van Groeningen C J
The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study.
Kaiserová Helena; Simunek Tomás; van der Vijgh Wim J F; Bast Aalt; Kvasnicková Eva
Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Wim van der Vijgh (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Jacobs Hilde; van der Vijgh Wim J F; Koek Ger H; Draaisma Guy J J; Moalin Mohamed; van Strijdonck Gino P F; Bast Aalt; Haenen Guido R M M
Characterization of the glutathione conjugate of the semisynthetic flavonoid monoHER.
Free radical biology & medicine 2009;46(12):1567-73.
2007: Bruynzeel A M E; Niessen H W M; Bronzwaer J G F; van der Hoeven J J M; Berkhof J; Bast A; van der Vijgh W J F; van Groeningen C J
The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study.
British journal of cancer 2007;97(8):1084-9.
2007: Kaiserová Helena; Simunek Tomás; van der Vijgh Wim J F; Bast Aalt; Kvasnicková Eva
Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase.
Biochimica et biophysica acta 2007;1772(9):1065-74.
2007: Bruynzeel Anna M E; Vormer-Bonne Suzanne; Bast Aalt; Niessen Hans W M; van der Vijgh Wim J F
Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice.
Cancer chemotherapy and pharmacology 2007;60(4):509-14.
2007: Bruynzeel A M E; Abou El Hassan M A; Schalkwijk C; Berkhof J; Bast A; Niessen H W M; van der Vijgh W J F
Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice.
British journal of cancer 2007;96(6):937-43.
2007: Bruynzeel A M E; Abou El Hassan M A; Torun E; Bast A; van der Vijgh W J F; Kruyt F A E
Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells.
British journal of cancer 2007;96(3):450-6.
2007: Bast A; Kaiserová H; den Hartog G J M; Haenen G R M M; van der Vijgh W J F
Protectors against doxorubicin-induced cardiotoxicity: flavonoids.
Cell biology and toxicology 2007;23(1):39-47.
2007: Bast Aalt; Haenen Guido R M M; Bruynzeel Anna M E; Van der Vijgh Wim J F
Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials.
Cardiovascular toxicology 2007;7(2):154-9.
2007: Rezk Bashir M; van der Vijgh Wim J F; Bast Aalt; Haenen Guido R M M
Alpha-tocopheryl phosphate is a novel apoptotic agent.
Frontiers in bioscience : a journal and virtual library 2007;12():2013-9.
2006: Bruynzeel Anna M E; Mul Paula P N; Berkhof Johannes; Bast Aalt; Niessen Hans W M; van der Vijgh Wim J F
The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Cancer chemotherapy and pharmacology 2006;58(5):699-702.
2006: Kroep J R; Smit E F; Giaccone G; Van der Born K; Beijnen J H; Van Groeningen C J; Van der Vijgh W J F; Postmus P E; Pinedo H M; Peters G J
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.
Cancer chemotherapy and pharmacology 2006;58(4):509-16.
2006: Willems Anja M; Bruynzeel Anne M; Kedde Marc A; van Groeningen Cees J; Bast Aalt; van der Vijgh Wim J
A phase I study of monohydroxyethylrutoside in healthy volunteers.
Cancer chemotherapy and pharmacology 2006;57(5):678-84.
2006: Peters Godefridus J; Van Moorsel Catharina J A; Lakerveld Bianca; Smid Kees; Noordhuis Paul; Comijn Elizabeth C; Weaver Dennis; Willey James C; Voorn Daphne; Van der Vijgh Wim J F; Pinedo Herbert M
Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
International journal of oncology 2006;28(1):237-44.
2005: Boven E; Westerman M; van Groeningen C J; Verschraagen M; Ruijter R; Zegers I; van der Vijgh W J F; Giaccone G
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
British journal of cancer 2005;92(9):1636-43.
2004: de Franceschi Lucia; Turrini Franco; Honczarenko Marek; Ayi Kojio; Rivera Alicia; Fleming Mark D; Law Terry; Mannu Franca; Kuypers Frans A; Bast Aalt; van der Vijgh Wim J F; Brugnara Carlo
In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia.
Haematologica 2004;89(11):1287-98.
2004: Verschraagen Miranda; Boven Epie; Torun Emine; Hausheer Frederick H; Bast Aalt; van der Vijgh Wim J F
Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
Biochemical pharmacology 2004;68(3):493-502.
2004: Rezk Bashir M; Haenen Guido R M M; Van Der Vijgh Wim J F; Bast Aalt
The extraordinary antioxidant activity of vitamin E phosphate.
Biochimica et biophysica acta 2004;1683(1-3):16-21.
2004: Giaccone G; González-Larriba J L; van Oosterom A T; Alfonso R; Smit E F; Martens M; Peters G J; van der Vijgh W J F; Smith R; Averbuch S; Fandi A
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(5):831-8.
2004: Verschraagen M; Boven E; Torun E; Erkelens C A M; Hausheer F H; van der Vijgh W J F
Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.
British journal of cancer 2004;90(8):1654-9.
2004: Rezk Bashir M; Haenen Guido R M M; van der Vijgh Wim J F; Bast Aalt
Lipoic acid protects efficiently only against a specific form of peroxynitrite-induced damage.
The Journal of biological chemistry 2004;279(11):9693-7.
2004: den Hartog Gertjan J M; Haenen Guido R M M; Boven Epie; van der Vijgh Wim J F; Bast Aalt
Lecithinized copper,zinc-superoxide dismutase as a protector against doxorubicin-induced cardiotoxicity in mice.
Toxicology and applied pharmacology 2004;194(2):180-8.
2003: Rezk Bashir M; Haenen Guido R M M; van der Vijgh Wim J F; Bast Aalt
Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity. Identification of the antioxidant pharmacophore.
FEBS letters 2003;555(3):601-5.
2003: Abou-El-Hassan M A I; Rabelink M J W E; van der Vijgh W J F; Bast A; Hoeben R C
A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro.
British journal of cancer 2003;89(11):2140-6.
2003: Abou El Hassan Mohamed A I; Kedde Marc A; Zwiers Ursula T H; Tourn E; Haenen Guido R M M; Bast Aalt; van der Vijgh Wim J F
Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice.
Cancer chemotherapy and pharmacology 2003;52(5):371-6.
2003: Verschraagen Miranda; Boven Epie; Ruijter Rita; van der Born Kasper; Berkhof Johannes; Hausheer Frederick H; van der Vijgh Wim J F
Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Clinical pharmacology and therapeutics 2003;74(2):157-69.
2003: Abou El Hassan M A I; Verheul H M W; Jorna A S; Schalkwijk C; van Bezu J; van der Vijgh W J F; Bast A
The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro.
British journal of cancer 2003;89(2):357-62.
2003: Verschraagen Miranda; Boven Epie; Zegers Ivon; Hausheer Frederick H; Van der Vijgh Wim J F
Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
Cancer chemotherapy and pharmacology 2003;51(6):525-9.
2003: Verschraagen Miranda; Kedde Marc A; Hausheer Frederick H; Van Der Vijgh Wim J F
The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.
Cancer chemotherapy and pharmacology 2003;51(6):499-504.
2003: Verschraagen Miranda; Zwiers T H Ursula; Torun Emine; Donker Martin G; Reinhoud Nico J; Van der Vijgh Wim J F
Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.
Journal of pharmaceutical sciences 2003;92(5):1040-50.
2003: Abou El Hassan Mohamed A I; Kedde Marc A; Zwiers Ursula T H; Bast Aalt; van der Vijgh Wim J F
The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice.
Cancer chemotherapy and pharmacology 2003;51(4):306-10.
2003: Abou El Hassan M A I; Heijn M; Rabelink M J W E; van der Vijgh W J F; Bast A; Hoeben R C
The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells.
Cancer gene therapy 2003;10(4):270-7.
2003: den Hartog G J M; Boots A W; Haenen G R M M; van der Vijgh W J F; Bast A
Lack of inhibition of endothelial nitric oxide synthase in the isolated rat aorta by doxorubicin.
Toxicology in vitro : an international journal published in association with BIBRA 2003;17(2):165-7.
2003: den Hartog Gertjan J M; Haenen Guido R M M; Vegt Erik; van der Vijgh Wim J F; Bast Aalt
Superoxide dismutase: the balance between prevention and induction of oxidative damage.
Chemico-biological interactions 2003;145(1):33-9.
2003: Verschraagen Miranda; Bosma Marjolein; Zwiers T H Ursula; Torun Emine; van der Vijgh Wim J F
Quantification of mesna and total mesna in kidney tissue by high-performance liquid chromatography with electrochemical detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;783(1):33-42.
2002: Rezk Bashir M; Haenen Guido R M M; van der Vijgh Wim J F; Bast Aalt
The antioxidant activity of phloretin: the disclosure of a new antioxidant pharmacophore in flavonoids.
Biochemical and biophysical research communications 2002;295(1):9-13.
2002: den Hartog Gertjan J M; Vegt Erik; van der Vijgh Wim J F; Haenen Guido R M M; Bast Aalt
Hypochlorous acid is a potent inhibitor of acetylcholinesterase.
Toxicology and applied pharmacology 2002;181(3):228-32.
2002: Verschraagen Miranda; van der Born Kasper; Zwiers T H Ursula; van der Vijgh Wim J F
Simultaneous determination of intact cisplatin and its metabolite monohydrated cisplatin in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;772(2):273-81.
2002: Boven E; Verschraagen M; Hulscher T M; Erkelens C A M; Hausheer F H; Pinedo H M; van der Vijgh W J F
BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
European journal of cancer (Oxford, England : 1990) 2002;38(8):1148-56.
2002: den Hartog Gertjan J M; Haenen Guido R M M; Vegt Erik; van der Vijgh Wim J F; Bast Aalt
Efficacy of HOCl scavenging by sulfur-containing compounds: antioxidant activity of glutathione disulfide?
Biological chemistry 2002;383(3-4):709-13.
2002: Kuenen Bart C; Rosen Lee; Smit Egbert F; Parson Mandy R N; Levi Marcel; Ruijter Rita; Huisman Holger; Kedde Marc A; Noordhuis Paul; van der Vijgh Wim J F; Peters Godefridus J; Cropp Gillian F; Scigalla Paul; Hoekman Klaus; Pinedo Herbert M; Giaccone Giuseppe
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1657-67.
2002: van Riel Johanna M G H; van Groeningen Cees J; Kedde Mark A; Gall Helen; Leisink Johanna M A; Gruia Gabriella; Pinedo Herbert M; van der Vijgh Wim J F; Giaccone Giuseppe
Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(2):405-12.
2001: van Acker F A; Hulshof J W; Haenen G R; Menge W M; van der Vijgh W J; Bast A
New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity.
Free radical biology & medicine 2001;31(1):31-7.
2001: Abou El Hassan M A; Kedde M A; Bast A; van der Vijgh W J
Determination of monohydroxyethylrutoside in heart tissue by high-performance liquid chromatography with electrochemical detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;757(1):191-6.
2001: van Acker F A; Boven E; Kramer K; Haenen G R; Bast A; van der Vijgh W J
Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1378-84.
2001: Verschraagen M; Zwiers T H; de Koning P E; Welink J; van der Vijgh W J
Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;753(2):293-302.
2001: El Hassan M A; Kedde M A; Bast A; van der Vijgh W J
High-performance liquid chromatography with electrochemical detection for the determination of 7-monohydroxyethylrutoside in plasma.
Journal of chromatography. B, Biomedical sciences and applications 2001;752(1):115-21.
2001: Heijnen C G; Haenen G R; van Acker F A; van der Vijgh W J; Bast A
Flavonoids as peroxynitrite scavengers: the role of the hydroxyl groups.
Toxicology in vitro : an international journal published in association with BIBRA 2001;15(1):3-6.
2000: Abou El Hassan M A; Touw D J; Wilhelm A J; Bast A; van der Vijgh W J
Stability of monoHER in an aqueous formulation for i.v. administration.
International journal of pharmaceutics 2000;211(1-2):51-6.
2000: van Moorsel C J; Pinedo H M; Smid K; Comijn E M; Voorn D A; Veerman G; Lakerveld B; Van der Vijgh W J; Giaccone G; Postmus P E; Peters G J
Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2420-9.
2000: van Acker F A; van Acker S A; Haenen G R; Bast A; van der Vijgh W J
In vitro screening of antitumour agents for cardiotoxicity by means of isolated mouse left atria.
Anticancer research 2000;20(6B):4483-7.
2000: Dijkgraaf-ten Bolscher M; Neele S J; Barto R; van der Vijgh W J; Netelenbos J C
Effect of estrogen on intestinal strontium absorption in postmenopausal women.
Maturitas 2000;36(3):195-201.
2000: van Acker F A; Hageman J A; Haenen G R; van Der Vijgh W J; Bast A; Menge W M
Synthesis of novel 3,7-substituted-2-(3',4'-dihydroxyphenyl)flavones with improved antioxidant activity.
Journal of medicinal chemistry 2000;43(20):3752-60.
2000: van Acker F A; Schouten O; Haenen G R; van der Vijgh W J; Bast A
Flavonoids can replace alpha-tocopherol as an antioxidant.
FEBS letters 2000;473(2):145-8.
2000: Dijkgraaf-ten Bolscher M; Barto R; Voorn D A; Compas D; Netelenbos J C; van der Vijgh W J
Influence of ovariectomy on extracellular fluid volume in rats: assessment of extracellular fluid volume by means of bromide.
The Journal of laboratory and clinical medicine 2000;135(4):303-8.
2000: van Groeningen C J; Van der Vijgh W J; Baars J J; Stieltjes H; Huibregtse K; Pinedo H M
Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1342-6.
2000: van Acker F A; van Acker S A; Kramer K; Haenen G R; Bast A; van der Vijgh W J
7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1337-41.
2000: Dijkgraaf-Ten Bolscher M; Netelenbos J C; Barto R; van Der Vijgh W J
Strontium as a marker for intestinal calcium absorption: the stimulatory effect of calcitriol.
Clinical chemistry 2000;46(2):248-51.
1999: Welink J; Boven E; Vermorken J B; Gall H E; van der Vijgh W J
Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2349-58.
1999: Ten Bolscher M; Netelenbos J C; Barto R; Van Buuren L M; Van der vijgh W J
Estrogen regulation of intestinal calcium absorption in the intact and ovariectomized adult rat.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1999;14(7):1197-202.
1999: van Moorsel C J; Pinedo H M; Veerman G; Bergman A M; Kuiper C M; Vermorken J B; van der Vijgh W J; Peters G J
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
British journal of cancer 1999;80(7):981-90.
1999: Goovaerts H G; Faes T J; de Valk-de Roo G W; ten Bolscher M; Netelenbosch J C; van der Vijgh W J; Heethaar R M
Estimation of extracellular volume by a two-frequency measurement.
Annals of the New York Academy of Sciences 1999;873():99-104.
1999: van Moorsel C J; Kroep J R; Pinedo H M; Veerman G; Voorn D A; Postmus P E; Vermorken J B; van Groeningen C J; van der Vijgh W J; Peters G J
Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):441-8.
1999: ten Bolscher M; de Valk-de Roo G W; Barto R; van der Vijgh W J; Netelenbos J C
Oestrogen has no short-term effect on intestinal strontium absorption in healthy postmenopausal women.
Clinical endocrinology 1999;50(3):387-92.
1999: Hoekman K; van der Vijgh W J; Vermorken J B
Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.
Drugs 1999;57(2):133-55.
1999: Welters M J; Fichtinger-Schepman A M; Baan R A; Jacobs-Bergmans A J; Kegel A; van der Vijgh W J; Braakhuis B J
Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
British journal of cancer 1999;79(1):82-8.
1999: Welters M J; Braakhuis B J; Jacobs-Bergmans A J; Kegel A; Baan R A; van der Vijgh W J; Fichtinger-Schepman A M
The potential of plantinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(1):97-103.
1998: Goovaerts H G; Faes T J; de Valk-de Roo G W; ten Bolscher M; Netelenbosch J C; van der Vijgh W J; Heethaar R M
Extra-cellular volume estimation by electrical impedance--phase measurement or curve fitting: a comparative study.
Physiological measurement 1998;19(4):517-26.
1998: van Acker S A; van Balen G P; van den Berg D J; Bast A; van der Vijgh W J
Influence of iron chelation on the antioxidant activity of flavonoids.
Biochemical pharmacology 1998;56(8):935-43.
1998: van Ark-Otte J; Kedde M A; van der Vijgh W J; Dingemans A M; Jansen W J; Pinedo H M; Boven E; Giaccone G
Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
British journal of cancer 1998;77(12):2171-6.
1998: Korst A E; Boven E; van der Sterre M L; Fichtinger-Schepman A M; van der Vijgh W J
Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
European journal of cancer (Oxford, England : 1990) 1998;34(3):412-6.
1998: Korst A E; van der Sterre M L; Gall H E; Fichtinger-Schepman A M; Vermorken J B; van der Vijgh W J
Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):331-6.
1997: Giaccone G; Linn S C; Welink J; Catimel G; Stieltjes H; van der Vijgh W J; Eeltink C; Vermorken J B; Pinedo H M
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2005-15.
1997: van Acker S A; Boven E; Kuiper K; van den Berg D J; Grimbergen J A; Kramer K; Bast A; van der Vijgh W J
Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(10):1747-54.
1997: Honkoop A H; van der Wall E; Feller N; Schuurhuis G J; van der Vijgh W J; Boven E; van Groeningen C J; Giaccone G; Hoekman K; Vermorken J B; Wagstaff J; Pinedo H M
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):957-62.
1997: Welters M J; Maliepaard M; Jacobs-Bergmans A J; Baan R A; Schellens J H; Ma J; van der Vijgh W J; Braakhuis B J; Fichtinger-Schepman A M
Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts.
Carcinogenesis 1997;18(9):1767-74.
1997: Korst A E; Eeltink C M; Vermorken J B; van der Vijgh W J
Pharmacokinetics of amifostine and its metabolites in patients.
European journal of cancer (Oxford, England : 1990) 1997;33(9):1425-9.
1997: Korst A E; van der Sterre M L; Eeltink C M; Fichtinger-Schepman A M; Vermorken J B; van der Vijgh W J
Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):697-703.
1997: Korst A E; Vermorken J B; van der Vijgh W J
High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine, WR 1065 and the disulfides in plasma.
Journal of chromatography. B, Biomedical sciences and applications 1997;693(1):167-74.
1997: Welters M J; Fichtinger-Schepman A M; Baan R A; Hermsen M A; van der Vijgh W J; Cloos J; Braakhuis B J
Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines.
International journal of cancer. Journal international du cancer 1997;71(3):410-5.
1997: Sips A J; Barto R; Netelenbos J C; van der Vijgh W J
Preclinical screening of the applicability of strontium as a marker for intestinal calcium absorption.
The American journal of physiology 1997;272(3 Pt 1):E422-8.
1997: Korst A E; Boven E; van der Sterre M L; Fichtinger-Schepman A M; van der Vijgh W J
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
British journal of cancer 1997;75(10):1439-46.
1996: van Acker S A; de Groot M J; van den Berg D J; Tromp M N; Donné-Op den Kelder G; van der Vijgh W J; Bast A
A quantum chemical explanation of the antioxidant activity of flavonoids.
Chemical research in toxicology 1996;9(8):1305-12.
1996: Boven E; de Jong J; Kuiper C M; Bast A; van der Vijgh W J
Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites.
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1382-7.
1996: Sips A J; van der Vijgh W J; Barto R; Netelenbos J C
Intestinal absorption of strontium chloride in healthy volunteers: pharmacokinetics and reproducibility.
British journal of clinical pharmacology 1996;41(6):543-9.
1996: Welink J; Pechstein B; van der Vijgh W J
Determination of the two diastereoisomers of lobaplatin (D-19466) in plasma ultrafiltrate of cancer patients with a normal or an impaired kidney or liver function by high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical applications 1996;675(1):107-11.
1996: Korst A E; Gall H E; Vermorken J B; van der Vijgh W J
Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Cancer chemotherapy and pharmacology 1996;39(1-2):162-6.
1996: van der Vijgh W J; Korst A E
Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
European journal of cancer (Oxford, England : 1990) 1996;32A Suppl 4():S26-30.
1996: van Acker S A; van den Berg D J; Tromp M N; Griffioen D H; van Bennekom W P; van der Vijgh W J; Bast A
Structural aspects of antioxidant activity of flavonoids.
Free radical biology & medicine 1996;20(3):331-42.
1996: van Acker S A; Kramer K; Voest E E; Grimbergen J A; Zhang J; van der Vijgh W J; Bast A
Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors.
Cancer chemotherapy and pharmacology 1996;38(1):95-101.
1995: Kramer K; Van Acker S A; Grimbergen J A; van den Berg D J; Van der Vijgh W J; Bast A
Effect of dimethyl sulfoxide (DMSO) on the electrocardiogram (ECG) in freely moving male Balb/c mice.
General pharmacology 1995;26(6):1403-7.
1995: Sips A J; van der Vijgh W J; Barto R; Netelenbos J C
Intestinal strontium absorption: from bioavailability to validation of a simple test representative for intestinal calcium absorption.
Clinical chemistry 1995;41(10):1446-50.
1995: van Acker S A; Tromp M N; Haenen G R; van der Vijgh W J; Bast A
Flavonoids as scavengers of nitric oxide radical.
Biochemical and biophysical research communications 1995;214(3):755-9.
1995: Ooms M E; Lips P; Roos J C; van der Vijgh W J; Popp-Snijders C; Bezemer P D; Bouter L M
Vitamin D status and sex hormone binding globulin: determinants of bone turnover and bone mineral density in elderly women.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1995;10(8):1177-84.
1995: Barto R; Sips A J; van der Vijgh W J; Netelenbos J C
Sensitive method for analysis of strontium in human and animal plasma by graphite furnace atomic absorption spectrophotometry.
Clinical chemistry 1995;41(8 Pt 1):1159-63.
1995: van Acker S A; Kramer K; Grimbergen J A; van den Berg D J; van der Vijgh W J; Bast A
Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.
British journal of pharmacology 1995;115(7):1260-4.
1995: Sips A J; Netelenbos J C; Barto R; van der Vijgh W J
Measurement of intestinal calcium absorption by using stable strontium.
Clinical science (London, England : 1979) 1995;89(1):107.
1995: Ooms M E; Roos J C; Bezemer P D; van der Vijgh W J; Bouter L M; Lips P
Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial.
The Journal of clinical endocrinology and metabolism 1995;80(4):1052-8.
1995: Peters G J; van der Vijgh W J
Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.
European journal of cancer (Oxford, England : 1990) 1995;31A Suppl 1():S1-7.
1995: Hüsken B C; de Jong J; Beekman B; Onderwater R C; van der Vijgh W J; Bast A
Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids.
Cancer chemotherapy and pharmacology 1995;37(1-2):55-62.
1994: van der Vijgh W J; Peters G J
Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects.
Seminars in oncology 1994;21(5 Suppl 11):2-7.
1994: Voest E E; van Acker S A; van der Vijgh W J; van Asbeck B S; Bast A
Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
Journal of molecular and cellular cardiology 1994;26(9):1179-85.
1994: Elders P J; Lips P; Netelenbos J C; van Ginkel F C; Khoe E; van der Vijgh W J; van der Stelt P F
Long-term effect of calcium supplementation on bone loss in perimenopausal women.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1994;9(7):963-70.
1994: Sips A J; Netelenbos J C; Barto R; Verburgh C A; Nieboer C; van der Vijgh W J
Topically applied low-dose calcitriol has no calciotropic effect in patients with stable plaque psoriasis.
Journal of the American Academy of Dermatology 1994;30(6):966-9.
1994: Sips A J; Netelenbos J C; Barto R; Lips P; van der Vijgh W J
One-hour test for estimating intestinal absorption of calcium by using stable strontium as a marker.
Clinical chemistry 1994;40(2):257-9.
1994: Treskes M; Boven E; van de Loosdrecht A A; Wijffels J F; Cloos J; Peters G J; Pinedo H M; van der Vijgh W J
Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.
European journal of cancer (Oxford, England : 1990) 1994;30A(2):183-7.
1993: van der Wiel H E; Lips P; Nauta J; Kwakkel G; Hazenberg G; Netelenbos J C; van der Vijgh W J
Intranasal calcitonin suppresses increased bone resorption during short-term immobilization: a double-blind study of the effects of intranasal calcitonin on biochemical parameters of bone turnover.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1993;8(12):1459-65.
1993: Klein I; Welink J; van der Vijgh W J
Determination of Elsamitrucin (BMY-28090) in plasma and urine by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1993;622(2):249-53.
1993: Kramer K; van Acker S A; Voss H P; Grimbergen J A; van der Vijgh W J; Bast A
Use of telemetry to record electrocardiogram and heart rate in freely moving mice.
Journal of pharmacological and toxicological methods 1993;30(4):209-15.
1993: van Acker S A; Voest E E; Beems D B; Madhuizen H T; de Jong J; Bast A; van der Vijgh W J
Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice.
Cancer research 1993;53(19):4603-7.
1993: Leeuwenkamp O R; van der Wiel H E; Lips P; van der Vijgh W J; Barto R; Greuter H; Netelenbos J C
Human pharmacokinetics of orally administered (24 R)-hydroxycalcidiol.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1993;31(7):419-26.
1993: Treskes M; van der Vijgh W J
WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Cancer chemotherapy and pharmacology 1993;33(2):93-106.
1992: de Jong J; Geijssen G J; Munniksma C N; Vermorken J B; van der Vijgh W J
Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(12):1897-906.
1992: Treskes M; Nijtmans L; Fichtinger-Schepman A M; van der Vijgh W J
Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.
Anticancer research 1992;12(6B):2261-5.
1992: Treskes M; Boven E; Holwerda U; Pinedo H M; van der Vijgh W J
Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Cancer research 1992;52(8):2257-60.
1992: Treskes M; Nijtmans L G; Fichtinger-Schepman A M; van der Vijgh W J
Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.
Biochemical pharmacology 1992;43(5):1013-9.
1992: de Jong J; Munniksma C N; Guérand W S; Bast A; van der Vijgh W J
Fully automated determination of a new anthracycline N-l-leucyldoxorubicin and six metabolites in plasma by high-performance liquid chromatography with on-line sample handling.
Journal of chromatography 1992;574(2):273-81.
1992: de Jong J; Klein I; Bast A; van der Vijgh W J
Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice.
Cancer chemotherapy and pharmacology 1992;31(2):156-60.
1992: van Laar J A; van der Wilt C L; Treskes M; van der Vijgh W J; Peters G J
Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.
Cancer chemotherapy and pharmacology 1992;31(2):97-102.
1992: Treskes M; Holwerda U; Nijtmans L G; Pinedo H M; van der Vijgh W J
The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.
Cancer chemotherapy and pharmacology 1992;29(6):467-70.
1992: Peters G J; van der Wilt C L; Gyergyay F; van Laar J A; Treskes M; van der Vijgh W J; Pinedo H M
Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil.
International journal of radiation oncology, biology, physics 1992;22(4):785-9.
1991: Treskes M; Holwerda U; Klein I; Pinedo H M; van der Vijgh W J
The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
Biochemical pharmacology 1991;42(11):2125-30.
1991: van der Vijgh W J
Clinical pharmacokinetics of carboplatin.
Clinical pharmacokinetics 1991;21(4):242-61.
1991: de Jong J; Guérand W S; Schoofs P R; Bast A; van der Vijgh W J
Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detection.
Journal of chromatography 1991;570(1):209-16.
1991: Netelenbos J C; van Ginkel F C; Lips P; Leeuwenkamp O R; Barto R; van der Vijgh W J; van der Wiel H; Hackeng W H
Effect of a single infusion of aminohydroxypropylidene on calcium and bone metabolism in healthy volunteers monitored during 2 months.
The Journal of clinical endocrinology and metabolism 1991;72(1):223-8.
1991: Leeuwenkamp O R; Neijt J P; van der Vijgh W J; Pinedo H M
Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate.
European journal of cancer (Oxford, England : 1990) 1991;27(10):1243-7.
1991: Tanis B C; Vermorken J B; ten Bokkel Huinink W W; Klein I; Gall H; van Oosterom A T; Simonetti G; McVie J G; van der Vijgh W J; Pinedo H M
Phase I study of spiroplatin.
European journal of cancer (Oxford, England : 1990) 1991;27(3):268-73.
1990: Leeuwenkamp O R; van der Vijgh W J; Hüsken B C; Lips P; Netelenbos J C
Human pharmacokinetics of orally administered strontium.
Calcified tissue international 1990;47(3):136-41.
1990: de Jong J; Maessen P A; Akkerdaas A; Cheung S F; Pinedo H M; van der Vijgh W J
Sensitive method for the determination of daunorubicin and all its known metabolites in plasma and heart by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1990;529(2):359-68.
1990: Peters G J; Schwartsmann G; Nadal J C; Laurensse E J; van Groeningen C J; van der Vijgh W J; Pinedo H M
In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Cancer research 1990;50(15):4644-9.
1990: Lips P; van Ginkel F C; Netelenbos J C; Wiersinga A; van der Vijgh W J
Lower mobility and markers of bone resorption in the elderly.
Bone and mineral 1990;9(1):49-57.
1990: van der Vijgh W J; Maessen P A; Pinedo H M
Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice.
Cancer chemotherapy and pharmacology 1990;26(1):9-12.
1990: Schwartsmann G; Dodion P; Vermorken J B; ten Bokkel Huinink W W; Joggi J; Winograd B; Gall H; Simonetti G; van der Vijgh W J; van Hennik M B
Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
Cancer chemotherapy and pharmacology 1990;25(5):345-51.
1989: Schwartsmann G; van der Vijgh W J; van Hennik M B; Klein I; Vermorken J B; Dodion P; ten Bokkel Huinink W W; Joggi G; Gall H; Crespeigne N
Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.
European journal of cancer & clinical oncology 1989;25(12):1675-81.
1989: Jongen M; van der Vijgh W J; Netelenbos J C; Postma G J; Lips P
Pharmacokinetics of 24,25-dihydroxyvitamin D3 in humans.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1989;21(10):577-80.
1989: Leeuwenkamp O R; van der Vijgh W J; Hüsken B C; Lips P; Netelenbos J C
Quantification of strontium in plasma and urine with flameless atomic absorption spectrometry.
Clinical chemistry 1989;35(9):1911-4.
1988: Lips P; Wiersinga A; van Ginkel F C; Jongen M J; Netelenbos J C; Hackeng W H; Delmas P D; van der Vijgh W J
The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects.
The Journal of clinical endocrinology and metabolism 1988;67(4):644-50.
1988: van der Vijgh W J; van Velzen D; van der Poort J S; Schlüper H M; Mross K; Feijen J; Pinedo H M
Morphometric study of myocardial changes during doxorubicin-induced cardiomyopathy in mice.
European journal of cancer & clinical oncology 1988;24(10):1603-8.
1988: van der Vijgh W J; Elferink F; Vermorken J B; ten Bokkel Huinink W W; Klein I; Gall H E; Simonetti G; McVie J G; Pinedo H M
Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.
European journal of cancer & clinical oncology 1988;24(4):621-7.
1988: Mross K; Maessen P; van der Vijgh W J; Gall H; Boven E; Pinedo H M
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(3):517-26.
1988: Jongen M J; Kuiper S; van der Vijgh W J; Lips P; Netelenbos J C
Improvements in the simultaneous determination of calcidiol and calcitriol in human serum or plasma.
Journal of clinical chemistry and clinical biochemistry. Zeitschrift für klinische Chemie und klinische Biochemie 1988;26(1):25-8.
1988: Maessen P A; Pinedo H M; Mross K B; van der Vijgh W J
New method for the determination of doxorubicin, 4'-epidoxorubicin and all known metabolites in cardiac tissue.
Journal of chromatography 1988;424(1):103-10.
1988: Elferink F; van der Vijgh W J; Klein I; ten Bokkel Huinink W W; Dubbelman R; McVie J G
Pharmacokinetics of carboplatin after intraperitoneal administration.
Cancer chemotherapy and pharmacology 1988;21(1):57-60.
1987: Lips P; van Ginkel F C; Jongen M J; Rubertus F; van der Vijgh W J; Netelenbos J C
Determinants of vitamin D status in patients with hip fracture and in elderly control subjects.
The American journal of clinical nutrition 1987;46(6):1005-10.
1987: Elferink F; van der Vijgh W J; Klein I; Vermorken J B; Gall H E; Pinedo H M
Pharmacokinetics of carboplatin after i.v. administration.
Cancer treatment reports 1987;71(12):1231-7.
1987: van Hennik M B; van der Vijgh W J; Klein I; Elferink F; Vermorken J B; Winograd B; Pinedo H M
Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
Cancer research 1987;47(23):6297-301.
1987: van der Vijgh W J; Van Velzen D; Van der Poort J S; Schlüper H M; Mross K; Feijen J; Pinedo H M
Morphometric study of myocardial changes during puromycin aminonucleoside induced nephropathy in rats.
Anticancer research 1987;7(6):1111-5.
1987: Elferink F; van der Vijgh W J; ten Bokkel Huinink W W; Vermorken J B; Klein I; Winograd B; Knobf M K; Simonetti G; Gall H E; McVie J G
Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
British journal of cancer 1987;56(4):479-83.
1987: Maessen P A; Mross K B; Pinedo H M; van der Vijgh W J
Improved method for the determination of 4'-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatography.
Journal of chromatography 1987;417(2):339-46.
1987: Mross K; Maessen P; van der Vijgh W J; Bogdanowicz J F; Kurth K H; Pinedo H M
Absorption of epi-doxorubicin after intravesical administration in patients with in situ transitional cell carcinoma of the bladder.
European journal of cancer & clinical oncology 1987;23(5):505-8.
1987: Maessen P A; Mross K B; Pinedo H M; van der Vijgh W J
Metabolism of epidoxorubicin in animals: absence of glucuronidation.
Cancer chemotherapy and pharmacology 1987;20(1):85-7.
1986: Netelenbos J C; Asscheman H; Lips P; Van der Vijgh W J; Jongen M J; Van Ginkel F; Hackeng W H
Absence of effect of 24,25-dihydroxyvitamin D3 in primary hyperparathyroidism.
The Journal of clinical endocrinology and metabolism 1986;63(1):246-8.
1986: Winograd B; Vermorken J B; ten Bokkel Huinink W W; Simonetti G; Gall H E; Knobf M K; van der Vijgh W J; McVie J G; Pinedo H M
Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.
Cancer research 1986;46(4 Pt 2):2148-51.
1985: Boven E; Nauta M M; Schluper H M; Elferink F; van der Vijgh W J; Pinedo H M
Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice.
European journal of cancer & clinical oncology 1985;21(10):1253-60.
1985: Netelenbos J C; Jongen M J; van der Vijgh W J; Lips P; van Ginkel F C
Vitamin D status in urinary calcium stone formation.
Archives of internal medicine 1985;145(4):681-4.
1985: Boven E; van der Vijgh W J; Nauta M M; Schlüper H M; Pinedo H M
Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Cancer research 1985;45(1):86-90.
1985: Lips P; Bouillon R; Jongen M J; van Ginkel F C; van der Vijgh W J; Netelenbos J C
The effect of trauma on serum concentrations of vitamin D metabolites in patients with hip fracture.
Bone 1985;6(2):63-7.
1984: Jongen M J; Van Ginkel F C; van der Vijgh W J; Kuiper S; Netelenbos J C; Lips P
An international comparison of vitamin D metabolite measurements.
Clinical chemistry 1984;30(3):399-403.
1984: Jongen M J; van der Vijgh W J; Lips P; Netelenbos J C
Measurement of vitamin D metabolites in anephric subjects.
Nephron 1984;36(4):230-4.
1982: Jongen M J; van der Vijgh W J; van Beresteyn E C; van den Berg H; Bosch R; Hoogenboezem T; Visser T J; Netelenbos J C
Interlaboratory variation of vitamin D1) metabolite measurements.
Journal of clinical chemistry and clinical biochemistry. Zeitschrift für klinische Chemie und klinische Biochemie 1982;20(10):753-6.
1982: Lips P; Netelenbos J C; Jongen M J; van Ginkel F C; Althuis A L; van Schaik C L; van der Vijgh W J; Vermeiden J P; van der Meer C
Histomorphometric profile and vitamin D status in patients with femoral neck fracture.
Metabolic bone disease & related research 1982;4(2):85-93.
1981: Jongen M J; van der Vijgh W J; Willems H J; Netelenbos J C; Lips P
Simultaneous determination of 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, and 1,25-dihydroxyvitamin D in plasma or serum.
Clinical chemistry 1981;27(10):1757-60.
1981: Jongen M J; van der Vijgh W J; Willems H J; Netelenbos J C
Analysis for 1,25-dihydroxyvitamin D in human plasma, after a liquid-chromatographic purification procedure, with a modified competitive protein-binding assay.
Clinical chemistry 1981;27(3):444-50.

Sign-in to see more